Delta (DOR) and mu opioid receptors (MOR) can complex as heteromers, conferring functional properties in agonist binding, signaling and trafficking that can differ markedly from their homomeric counterparts. Because of these differences, DOR/MOR heteromers may be a novel therapeutic target in the treatment of pain. However, there are currently no ligands selective for DOR/MOR heteromers, and, consequently, their role in nociception remains unknown. In this study, we used a pharmacological opioid cocktail that selectively activates and stabilizes the DOR/MOR heteromer at the cell surface by blocking its endocytosis to assess its role in antinociception. We found that mice treated chronically with this drug cocktail showed a significant right shift in the ED50 for opioid-mediated analgesia, while mice treated with a drug that promotes degradation of the heteromer did not. Furthermore, promoting degradation of the DOR/MOR heteromer after the right shift in the ED50 had occurred, or blocking signal transduction from the stabilized DOR/MOR heteromer, shifted the ED50 for analgesia back to the left. Taken together, these data suggest an anti-analgesic role for the DOR/MOR heteromer in pain. In conclusion, antagonists selective for DOR/MOR heteromer could provide an avenue for alleviating reduced analgesic response during chronic pain treatment.
References
[1]
Scherrer G, Imamachi N, Cao Y-Q, Contet C, Mennicken F, et al. (2009) Dissociation of the Opioid Receptor Mechanisms that Control Mechanical and Heat Pain. Cell 137: 1148–1159.
[2]
Dykstra L, Granger A, Allen R, Zhang X, Rice K (2002) Antinociceptive effects of the selective delta opioid agonist SNC80 alone and in combination with mu opioids in the squirrel monkey titration procedure. Psychopharmacology 163: 420–429.
[3]
Stevenson GW, Folk JE, Linsenmayer DC, Rice KC, Negus SS (2003) Opioid Interactions in Rhesus Monkeys: Effects of delta+mu and delta+kappa Agonists on Schedule-Controlled Responding and Thermal Nociception. Journal of Pharmacology and Experimental Therapeutics 307: 1054–1064.
[4]
Zhang Z, Pan ZZ (2010) Synaptic Mechanism for Functional Synergism between delta- and mu-Opioid Receptors. The Journal of Neuroscience 30: 4735–4745.
[5]
Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, et al.. (2000) Heterodimerization of {micro} and delta Opioid Receptors: A Role in Opiate Synergy. J Neurosci 20: 110RC-.
[6]
Gomes I, Ijzerman AP, Ye K, Maillet EL, Devi LA (2011) G Protein-Coupled Receptor Heteromerization: A Role in Allosteric Modulation of Ligand Binding. Molecular Pharmacology 79: 1044–1052.
[7]
Hasbi A, Nguyen T, Fan T, Cheng R, Rashid A, et al. (2007) Trafficking of Preassembled Opioid mu-delta Heterooligomer-Gz Signaling Complexes to the Plasma Membrane: Coregulation by Agonists. Biochemistry 46: 12997–13009.
[8]
He S-Q, Zhang Z-N, Guan J-S, Liu H-R, Zhao B, et al. (2011) Facilitation of [mu]-Opioid Receptor Activity by Preventing [delta]-Opioid Receptor-Mediated Codegradation. Neuron 69: 120–131.
[9]
Kabli N, Martin N, Fan T, Nguyen T, Hasbi A, et al. (2010) Agonists at the δ-opioid receptor modify the binding of μ-receptor agonists to the μ–δ receptor hetero-oligomer. British Journal of Pharmacology 161: 1122–1136.
[10]
Milan-Lobo L, Whistler JL (2011) Heteromerization of the micro- and delta-Opioid Receptors Produces Ligand-Biased Antagonism and Alters micro-Receptor Trafficking. Journal of Pharmacology and Experimental Therapeutics 337: 868–875.
[11]
Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, et al. (2004) A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proceedings of the National Academy of Sciences of the United States of America 101: 5135–5139.
[12]
Wang H-B, Zhao B, Zhong Y-Q, Li K-C, Li Z-Y, et al. (2010) Coexpression of delta- and mu-opioid receptors in nociceptive sensory neurons. Proceedings of the National Academy of Sciences 107: 13117–13122.
[13]
Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, et al. (2012) Crystal structure of the [micro]-opioid receptor bound to a morphinan antagonist. Nature 485: 321–326.
[14]
Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, et al. (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proceedings of the National Academy of Sciences of the United States of America 102: 9050–9055.
[15]
Finn AK, Whistler JL (2001) Endocytosis of the Mu Opioid Receptor Reduces Tolerance and a Cellular Hallmark of Opiate Withdrawal. Neuron 32: 829–839.
[16]
Kostenis E (2001) Is G[alpha]16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends in Pharmacological Sciences 22: 560–564.
[17]
Raehal KM, Bohn LM (2011) The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 60: 58–65.
[18]
Kim JA, Bartlett S, He L, Nielsen CK, Chang AM, et al. (2008) Morphine-Induced Receptor Endocytosis in a Novel Knockin Mouse Reduces Tolerance and Dependence. Current Biology 18: 129–135.
[19]
Raynor K, Kong H, Chen Y, Yasuda K, Yu L, et al. (1994) Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Molecular Pharmacology 45: 330–334.
[20]
Kest B, Lee CE, McLemore GL, Inturrisi CE (1996) An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Research Bulletin 39: 185–188.
[21]
Zhu Y, King MA, Schuller AGP, Nitsche JF, Reidl M, et al. (1999) Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in [delta] Opioid Receptor Knockout Mice. Neuron 24: 243–252.
[22]
Abdelhamid E, Sultana Portoghese, Takemori (1991) Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 299–303.
[23]
Daniels DJ, Lenard NR, Etienne CL, Law P-Y, Roerig SC, et al. (2005) Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proceedings of the National Academy of Sciences of the United States of America 102: 19208–19213.
[24]
Fundytus ME, Schiller PW, Shapiro M, Weltrowska G, Coderre TJ (1995) Attenuation of morphine tolerance and dependence with the highly selective [delta]-opioid receptor antagonist TIPP[[psi]]. European Journal of Pharmacology 286: 105–108.
[25]
Abul-Husn NS, Sutak M, Milne B, Jhamandas K (2007) Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of μ- and δ-opioid receptor antagonists. British Journal of Pharmacology 151: 877–887.
[26]
Hepburn M, Little P, Gingras J, Kuhn C (1997) Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats. J Pharmacol Exp Ther 281: 1350–1356.
[27]
McNaull B, Trang T, Sutak M, Jhamandas K (2007) Inhibition of tolerance to spinal morphine antinociception by low doses of opioid receptor antagonists. European Journal of Pharmacology 560: 132–141.
[28]
Arttamangkul S, Quillinan N, Low MJ, von Zastrow M, Pintar J, et al. (2008) Differential Activation and Trafficking of Mu-Opioid Receptors in Brain Slices. Molecular Pharmacology 74: 972–979.
[29]
Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, et al. (1998) Mu-Opioid Receptor Internalization: Opiate Drugs Have Differential Effects on a Conserved Endocytic Mechanism In Vitro and in the Mammalian Brain. Molecular Pharmacology 53: 377–384.
[30]
He L, Whistler JL (2005) An Opiate Cocktail that Reduces Morphine Tolerance and Dependence. Current Biology 15: 1028–1033.
[31]
Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, et al. (2010) Increased Abundance of Opioid Receptor Heteromers After Chronic Morphine Administration. Sci Signal 3: ra54.
[32]
Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, et al. (2001) Switching From Morphine to Methadone to Improve Analgesia and Tolerability in Cancer Patients: A Prospective Study. Journal of Clinical Oncology 19: 2898–2904.
[33]
Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, et al. (2009) Frequency, Indications, Outcomes, and Predictive Factors of Opioid Switching in an Acute Palliative Care Unit. Journal of Pain and Symptom Management 37: 632–641.
[34]
Bailey CP, Connor M (2005) Opioids: cellular mechanisms of tolerance and physical dependence. Current Opinion in Pharmacology 5: 60–68.
[35]
George SR, Fan T, Xie Z, Tse R, Tam V, et al. (2000) Oligomerization of mu- and delta-Opioid Receptors. Journal of Biological Chemistry 275: 26128–26135.
[36]
Fan T, Varghese G, Nguyen T, Tse R, O’Dowd BF, et al. (2005) A Role for the Distal Carboxyl Tails in Generating the Novel Pharmacology and G Protein Activation Profile of mu- and delta- Opioid Receptor Hetero-oligomers. Journal of Biological Chemistry 280: 38478–38488.
[37]
Rozenfeld R, Devi LA (2007) Receptor heterodimerization leads to a switch in signaling: {beta}-arrestin2-mediated ERK activation by {micro}-{delta} opioid receptor heterodimers. FASEB J 21: 2455–2465.
[38]
Bohn LM, Gainetdinov RR, Lin F-T, Lefkowitz RJ, Caron MG (2000) [mu]-Opioid receptor desensitization by [beta]-arrestin-2 determines morphine tolerance but not dependence. Nature 408: 720–723.
[39]
Bie B, Pan Z (2007) Trafficking of central opioid receptors and descending pain inhibition. Molecular Pain 3: 37.
[40]
Cahill CM, Holdridge SV, Morinville A (2007) Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci 28: 23–31.
